{"ticker": {"uuid": "3fbe4e8d-e641-4a23-954e-c3ae5c4a56dc", "symbol": "UPB", "name": "Upstream Bio, Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ETFs Investing in Upstream Bio, Inc. Stocks", "summary": "This article lists various ETFs that hold shares of Upstream Bio, Inc. (UPB), providing details such as market value, weight in the ETF, issuer, management style, expense ratio, AUM, price, and performance metrics. The information aims to help investors identify funds that offer ", "url": "https://www.tradingview.com/symbols/NASDAQ-UPB/etfs/", "source_name": "TradingView", "published_at": "2026-07-16T18:39:50", "published_display": "16 Jul 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPWTlUOFg1MFRIZ1BmWEVRTTNxbzVvTzhBem9pREIwS3M3WVRleVpBQWdwSlBaZFg0VTBMYV9nSTZNTTBDYWlwelpDVTV1d0NrZTktaTBoNjlodzhOY0Y2MmpsNG5IYmx1NlZrblU2QnF1QkxrU3I5SEl6VzVvc3h0TVVwdmlyS3plX3EwelA2Vm82bGZESEdwNC1R?oc=5", "source_name": "Market source", "published_at": "2026-07-14T16:00:04+00:00", "published_display": "14 Jul 2026 16:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Price to earnings forward of Upstream Bio, Inc. \u2013 NASDAQ:UPB", "summary": "This article provides the \"Price to earnings forward\" metric for Upstream Bio, Inc. (NASDAQ: UPB) as listed on TradingView. It indicates that the market was closed with no trades recorded at the time of data retrieval. The report presents the value and percentage change for this ", "url": "https://www.tradingview.com/symbols/NASDAQ-UPB/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T09:10:54", "published_display": "08 Jul 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Upstream Bio, Inc. \u2013 NASDAQ:UPB", "summary": "This article provides the \"Price to book forward\" value for Upstream Bio, Inc. (NASDAQ: UPB). It includes basic financial information and indicates that the market was closed with no trades at the time of publication. The data is presented within the context of a financial market", "url": "https://www.tradingview.com/symbols/NASDAQ-UPB/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T13:42:23", "published_display": "07 Jul 2026 13:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UPB - Upstream Bio Inc Dividends", "summary": "This article provides detailed financial data and performance metrics for Upstream Bio Inc. (UPB). It lists various financial ratios, stock performance over different periods, insider and institutional ownership, and analyst recommendations, noting that the company does not curre", "url": "https://finviz.com/stock?t=UPB&ty=dv", "source_name": "Finviz", "published_at": "2026-07-06T04:39:31", "published_display": "06 Jul 2026 04:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Upstream Bio, Inc. \u2013 NASDAQ:UPB", "summary": "The article focuses on the \"Price to sales forward\" metric for Upstream Bio, Inc. (NASDAQ: UPB). It provides a snapshot of the company's financial data on TradingView, indicating that the market was closed at the time of viewing. The content is primarily a data point with no furt", "url": "https://www.tradingview.com/symbols/NASDAQ-UPB/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T09:40:51", "published_display": "04 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in UpStream Bio Inc. (UPB)", "summary": "This article examines the historical performance of a $1,000 investment in UpStream Bio Inc. (UPB), a clinical-stage biotechnology company focused on inflammatory diseases. It provides detailed information on UPB's core drug candidate, verekitug, its mechanism of action, and its ", "url": "https://www.stocktitan.net/tools/stock-return-calculator/UPB", "source_name": "Stock Titan", "published_at": "2026-07-04T05:11:19", "published_display": "04 Jul 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Watching Upstream Bio's (NASDAQ:UPB) Cash Burn Situation", "summary": "This article examines Upstream Bio's cash burn rate and its implications for the company's future operations. It analyzes the current cash reserves against the burn rate to estimate how long the company can continue funding its activities without additional capital. The article h", "url": "https://www.moomoo.com/news/post/72406755/here-s-why-we-re-watching-upstream-bio-s-nasdaq", "source_name": "Moomoo", "published_at": "2026-07-02T14:41:07", "published_display": "02 Jul 2026 14:41", "sentiment": "negative", "sentiment_pct": 29, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Upstream Bio, Inc. \u2013 NASDAQ:UPB", "summary": "The article focuses on the enterprise value to EBIT forward ratio for Upstream Bio, Inc., trading under the NASDAQ symbol UPB. It appears to be a financial data point presented within a trading platform context, with placeholders for actual financial figures.", "url": "https://www.tradingview.com/symbols/NASDAQ-UPB/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T17:40:34", "published_display": "29 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio, Inc. Actuals & Estimates (NASDAQ:UPB)", "summary": "This article provides an overview of Upstream Bio, Inc. (NASDAQ: UPB) stock, including its current price, market capitalization, historical performance, and analyst forecasts. It also details key financial actuals and estimates such as earnings per share and revenue, indicating t", "url": "https://www.tradingview.com/symbols/NASDAQ-UPB/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T19:09:53", "published_display": "26 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio, Inc. (UPB) reports Q1 loss, beats revenue estimates", "summary": "Upstream Bio, Inc. (UPB) reported a Q1 loss per share of $0.93, which was lower than the analyst estimate of a $1.09 loss per share. The company also announced Q1 revenue of $180,000, surpassing the analyst consensus estimate of $170,000.", "url": "https://www.msn.com/en-us/money/other/upstream-bio-inc-upb-reports-q1-loss-beats-revenue-estimates/ar-AA236hGq?ocid=BingNewsVerp", "source_name": "MSN", "published_at": "2026-06-26T11:09:53", "published_display": "26 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage?", "summary": "Upstream Bio, Inc. (NASDAQ:UPB) is highlighted as a promising small-cap stock following new analyst coverage from H.C. Wainwright, which initiated a Buy rating and a $36 price target. The analyst praised the company's lead candidate, verekitug, an antibody targeting the thymic st", "url": "https://www.insidermonkey.com/blog/is-upstream-bio-inc-upb-a-rising-biotech-opportunity-after-new-analyst-coverage-1788980/", "source_name": "Insider Monkey", "published_at": "2026-06-25T08:42:00", "published_display": "25 Jun 2026 08:42", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Upstream Bio, Inc. (UPB) the Best Low Priced Stocks to Get Rich in 2026?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPTTNHejRwTVFRTVgtRC1KRjgzQ0R3R0hSakVTVkxkR2VRczRaZXJlWHRpVUVVaFZpTFdFZ3ExaElEMzIxY3pieXcwdTd6emhSNmpzblgyNTJzSlVKTDdxRW9DQUg1V3V5ekk0Y0xRTzRuM0JLMWl1TFZadDcwMHFFYXMzZGo3ODNqNXNELXU3UVB3Zkd4?oc=5", "source_name": "Market source", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio Inc (UPB) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Upstream Bio Inc (UPB), covering its current price momentum, support and resistance levels, and various technical indicators and moving averages. According to the analysis, UPB's price momentum score is 6.46, and it's trading between ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-upb/technical", "source_name": "TradingKey", "published_at": "2026-06-18T01:40:17", "published_display": "18 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio Inc (UPB) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Upstream Bio Inc's (UPB) dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years and shows no data for past stock splits. The page includes current stock price information, marke", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-upb/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:39:18", "published_display": "17 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio Inc (UPB) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Upstream Bio Inc (UPB), noting its current valuation score is 8.14, ranking 168 out of 388 in the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -2.04 and states that relevant data for P/B", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-upb/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T04:10:07", "published_display": "17 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio Reports Positive Phase 2 Results for Verekitug in Chronic Rhinosinusitis with Nasal Polyps, Achieving Clinically Meaningful Improvements in Key Symptoms", "summary": "Upstream Bio announced positive Phase 2 results for its drug verekitug in treating chronic rhinosinusitis with nasal polyps (CRSwNP). The trial demonstrated significant improvements in nasal polyp scores and key secondary endpoints like nasal congestion and total symptom scores, ", "url": "https://www.quiverquant.com/news/Upstream+Bio+Reports+Positive+Phase+2+Results+for+Verekitug+in+Chronic+Rhinosinusitis+with+Nasal+Polyps%2C+Achieving+Clinically+Meaningful+Improvements+in+Key+Symptoms", "source_name": "Quiver Quantitative", "published_at": "2026-06-14T14:10:00", "published_display": "14 Jun 2026 14:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026", "summary": "Upstream Bio presented new responder analyses from its Phase 2 VIBRANT trial for verekitug, showing clinically meaningful improvements in chronic rhinosinusitis with nasal polyps (CRSwNP). The data indicated that approximately 80% of participants treated with verekitug every thre", "url": "https://www.globenewswire.com/news-release/2026/06/14/3311448/0/en/upstream-bio-presents-new-responder-analyses-demonstrating-clinically-meaningful-improvements-in-crswnp-in-significant-majority-of-participants-treated-with-verekitug-in-the-phase-.html", "source_name": "GlobeNewswire", "published_at": "2026-06-14T14:09:25", "published_display": "14 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quarterly nasal polyp treatment improved symptoms for most trial patients", "summary": "Upstream Bio presented new analyses from its Phase 2 VIBRANT trial for verekitug, showing clinically meaningful improvements in chronic rhinosinusitis with nasal polyps (CRSwNP) symptoms for a significant majority of patients with quarterly dosing. Approximately 80% achieved impr", "url": "https://www.stocktitan.net/news/UPB/upstream-bio-presents-new-responder-analyses-demonstrating-nf8nz0204l8c.html", "source_name": "Stock Titan", "published_at": "2026-06-14T14:09:25", "published_display": "14 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio Cut to Neutral From Overweight by JP Morgan", "summary": "JP Morgan has downgraded Upstream Bio's rating from Overweight to Neutral. This change in rating suggests a revised outlook on the company's stock performance by the investment bank.", "url": "https://www.moomoo.com/news/post/71464057/upstream-bio-cut-to-neutral-from-overweight-by-jp-morgan?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-13T12:10:12", "published_display": "13 Jun 2026 12:10", "sentiment": "negative", "sentiment_pct": 31, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan Downgrades Upstream Bio to Neutral From Overweight, Cuts Price Target to $8 From $35", "summary": "JPMorgan downgraded Upstream Bio (UPB) from Overweight to Neutral and significantly cut its price target from $35 to $8. This adjustment reflects a revised outlook from the investment bank regarding the biotechnology company. Upstream Bio is a clinical-stage biotechnology company", "url": "https://www.marketscreener.com/news/jpmorgan-downgrades-upstream-bio-to-neutral-from-overweight-cuts-price-target-to-8-from-35-ce7f5cd9d889f123", "source_name": "marketscreener.com", "published_at": "2026-06-12T11:09:34", "published_display": "12 Jun 2026 11:09", "sentiment": "negative", "sentiment_pct": 8, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "J.P. Morgan Downgrades UpStream Bio(UPB.US) to Hold Rating, Announces Target Price $8", "summary": "J.P. Morgan has downgraded UpStream Bio (UPB.US) from an Overweight to a Hold rating. The firm also announced a new target price of $8 for the company's stock. This change in rating reflects J.P. Morgan's updated outlook on UpStream Bio's financial performance and market potentia", "url": "https://www.moomoo.com/news/post/71452917/jp-morgan-downgrades-upstream-bio-upbus-to-hold-rating-announces", "source_name": "Moomoo", "published_at": "2026-06-12T10:09:34", "published_display": "12 Jun 2026 10:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio Shareholders Elect Directors, Ratify 2026 Auditor", "summary": "Upstream Bio, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders elected two Class II directors, H. Edward Fleming, Jr., M.D., and Liam Ratcliffe, M.B.Ch.B., Ph.D., M.B.A., to serve until the 2029 annual meeting. Investors also ratified PricewaterhouseCoopers L", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/2430605/upstream-bio-shareholders-elect-directors-ratify-2026-auditor/", "source_name": "The Globe and Mail", "published_at": "2026-06-10T16:10:12", "published_display": "10 Jun 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026", "summary": "Upstream Bio announced that additional efficacy data from its Phase 2 VIBRANT trial of verekitug in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) will be presented in an oral session at the European Academy of Allergy and Clinical Immunology (EAACI) 2026 Congres", "url": "https://www.globenewswire.com/news-release/2026/06/08/3307953/0/en/upstream-bio-to-showcase-additional-efficacy-data-from-the-phase-2-vibrant-trial-of-verekitug-in-crswnp-in-oral-session-at-eaaci-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-06-08T22:08:53", "published_display": "08 Jun 2026 22:08", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nasal polyp drug Verekitug Phase 2 data to be aired at EAACI 2026", "summary": "Upstream Bio (NASDAQ: UPB) will present additional efficacy data from its Phase 2 VIBRANT trial of verekitug for chronic rhinosinusitis with nasal polyps (CRSwNP) at the EAACI 2026 Congress on June 14, 2026. The presentation will feature a responder analysis highlighting clinical", "url": "https://www.stocktitan.net/news/UPB/upstream-bio-to-showcase-additional-efficacy-data-from-the-phase-2-8nweqwjlmf8w.html", "source_name": "Stock Titan", "published_at": "2026-06-08T10:39:07", "published_display": "08 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio (UPB) price target decreased by 18.03% to 51.00", "summary": "Upstream Bio's price target has been decreased by 18.03% to $51.00. This adjustment indicates a notable change in the financial outlook for the company.", "url": "http://www.msn.com/en-us/money/topstocks/upstream-bio-upb-price-target-decreased-by-1803-to-5100/ar-AA1RPAnE?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-06-04T20:10:06", "published_display": "04 Jun 2026 20:10", "sentiment": "negative", "sentiment_pct": 13, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/upstream-bio-present-goldman-sachs-110000903.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T11:00:00+00:00", "published_display": "03 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HC Wainwright Initiates Upstream Bio at Buy With $36 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/hc-wainwright-initiates-upstream-bio-103025385.html", "source_name": "MT Newswires", "published_at": "2026-06-03T10:30:25+00:00", "published_display": "03 Jun 2026 10:30", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio: The Reset Is The Opportunity, Initiating At Buy (NASDAQ:UPB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPN0dxNnhiVkgwWHRxNnBwbDZ6RnFIM0xkUU5vVVIteWEzanJGRzBkMkVobEExLXJTY0hwSGFkRnJDcUpxU1NfVUJ0VnhkTmRreXFrVDU0UndxSG9WT3JXeUZQOXdUQTByYUcwdGFJbUdhazdyZGR1cmVtY2RkeXExNno5c0YzV0xVTFRDNlFFU3kwbHhianhmclc4N3ZxMWJGVm9wU3hkMA?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/upstream-bio-presents-data-phase-153000153.html", "source_name": "GlobeNewswire", "published_at": "2026-05-18T15:30:00+00:00", "published_display": "18 May 2026 15:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Mizuho Adjusts Price Target on Upstream Bio to $50 From $51, Maintains Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/mizuho-adjusts-price-target-upstream-102046798.html", "source_name": "MT Newswires", "published_at": "2026-05-14T10:20:46+00:00", "published_display": "14 May 2026 10:20", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Should I buy Upstream Bio, Inc. (UPB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMia0FVX3lxTFBrcjB6YVhJOFFKWmhvbHZKZU1ZVTBXNUNONEpURkVlbG1odmFnbVd0bE1wZ2pXWEpsbmNBdGF4RDI2QkVIYkdaU2RVSV9hbnQtSk1mT21FcVdHZnhXeVd5TGM1Q2VZcWw0RUp3?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Companies Like Upstream Bio (NASDAQ:UPB) Are In A Position To Invest In Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNWTJkcnBwbmtxN205dzdCLTlDZGhGQUttRzhEVENnTVRhTEV4SXQ3ak1TN2xOQ3N3ODhhYV9OSTBabm9HbFh3RnlHODVvOExnVkFIekRvZldsOGM3SmJrYlhhUERaZF9IeENiTk1ZRVk4SW1yclVIWjcxLUZrc1pReldjanBMdw?oc=5", "source_name": "Market source", "published_at": "2026-02-15T08:00:00+00:00", "published_display": "15 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio: Hold Rating As Verekitug Faces Competition Among Latest Asthma Data (UPB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNSDgxSi1hdXFQQUlyRERkdVlpQi1KY3VZc0NjVjc2TFVCQVhheExGbzR4dGRMUXN1YlVPTXFwM1ZCSkNKR2g1SXZQb2Y3NEExM09WT01BWnUwRWtXSWpoV3VEelFIV1BSNmlCdFVkaHRqb0VCU3JwdGJKdU51cmZ3OVYwWUVFcTBXdWVNWHhfMUZScWY4Mkp0Qm94eUZKcUF6UGZsQXNiYjVvZFQxX1BsZXl6OUk4UGpGMjY5UWZB?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Upstream Bio (UPB) Valuation After Recent Share Price Volatility", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio\u2019s stock drops 47% on verekitug Phase II asthma data", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTE5UekJzNWN5UFhZTjJ0N1VwWEwtVEZmQjJuSHVzeEJ5TEF4WkszS1ZWUXpGZkN0YUVseU1UZF8ydUpSeF9vOTJIMHpqeHlYNHZfRmZVTVF4ZktqaWRDSHNjdk0xRmI0U0lzb3dmbkVpTUlTVWYwLW13SGF2T04xQQ?oc=5", "source_name": "Market source", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio Stock Pre-Market (+15%) : Positive Phase 2 Asthma Trial Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNbjcxbXNDTHJ4T05VMTVoSkttTFNqX1FFc2t3a2xQdTNTVUhYTjR5aUlWVzMxOW9nNzFBZGlfR1hnVkpUNmpIUmh4bm56bUlKRndTMkFON3drWVVXWDRQcENsZkxfQk1vX3ZSOWtpMXdvY3FGYUFLV2E2bmpYQVNYdXNIcHN3NU5XRHJyVDc0NkctRnhxbEtJUTg3VjdMSjVWWTYtZ1FJaUVwY3lxb1IwbFFBY296NUxFV0YtejJ3c0NHR0ZNdmc?oc=5", "source_name": "Trefis", "published_at": "2026-02-11T08:00:00+00:00", "published_display": "11 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio stock tumbles after mixed Phase 2 asthma trial results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPN2FKYWpvWGgwNFYzQXBSS0pCVzNlNzFWWHhWdTRmTld5WW1xU2JfbnFTRmlFTGhZYlJORktkOC16ZGZKY2twNjFvMXd3YW44YnU0cXF2OXVBQnBrclpzUDBsN0daSU9lM1BDc3lKNmkyc2tsU2pJOTN5dHp4c1Z6NkE5aVpMNnBpTUtaMW1MaENyMGU2VGVJNldHUHVKQm1YUWg1NlR4aEFOX1BOZTNMN0lfWlh1LW1jZG5KRFoyNkNyb08xdzRGNA?oc=5", "source_name": "Investing.com", "published_at": "2026-02-11T08:00:00+00:00", "published_display": "11 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Upstream Bio (UPB) Is Up 12.2% After JPM Debut And VALINAT Hopes", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-16T08:00:00+00:00", "published_display": "16 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio (UPB) Stock Price, News & Analysis $UPB", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWEFVX3lxTE5NcmUwckpPdER1SUtta3ZsS3IyVVUwU1Y4a1RDSlBRMHNoNDVrZnNxd2dQX0NFNE5JLVRBUkZBeks0OVZMQ2VydVBFT2kzekNBejh6d2FlMUM?oc=5", "source_name": "MarketBeat", "published_at": "2024-10-12T01:44:50+00:00", "published_display": "12 Oct 2024 01:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "ETFs Investing in Upstream Bio, Inc. Stocks", "summary": "This article lists various ETFs that hold shares of Upstream Bio, Inc. (UPB), providing details such as market value, weight in the ETF, issuer, management style, expense ratio, AUM, price, and performance metrics. The information aims to help investors identify funds that offer ", "url": "https://www.tradingview.com/symbols/NASDAQ-UPB/etfs/", "source_name": "TradingView", "published_at": "2026-07-16T18:39:50", "published_display": "16 Jul 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPWTlUOFg1MFRIZ1BmWEVRTTNxbzVvTzhBem9pREIwS3M3WVRleVpBQWdwSlBaZFg0VTBMYV9nSTZNTTBDYWlwelpDVTV1d0NrZTktaTBoNjlodzhOY0Y2MmpsNG5IYmx1NlZrblU2QnF1QkxrU3I5SEl6VzVvc3h0TVVwdmlyS3plX3EwelA2Vm82bGZESEdwNC1R?oc=5", "source_name": "Market source", "published_at": "2026-07-14T16:00:04+00:00", "published_display": "14 Jul 2026 16:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Upstream Bio, Inc. \u2013 NASDAQ:UPB", "summary": "This article provides the \"Price to earnings forward\" metric for Upstream Bio, Inc. (NASDAQ: UPB) as listed on TradingView. It indicates that the market was closed with no trades recorded at the time of data retrieval. The report presents the value and percentage change for this ", "url": "https://www.tradingview.com/symbols/NASDAQ-UPB/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T09:10:54", "published_display": "08 Jul 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Upstream Bio, Inc. \u2013 NASDAQ:UPB", "summary": "This article provides the \"Price to book forward\" value for Upstream Bio, Inc. (NASDAQ: UPB). It includes basic financial information and indicates that the market was closed with no trades at the time of publication. The data is presented within the context of a financial market", "url": "https://www.tradingview.com/symbols/NASDAQ-UPB/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T13:42:23", "published_display": "07 Jul 2026 13:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UPB - Upstream Bio Inc Dividends", "summary": "This article provides detailed financial data and performance metrics for Upstream Bio Inc. (UPB). It lists various financial ratios, stock performance over different periods, insider and institutional ownership, and analyst recommendations, noting that the company does not curre", "url": "https://finviz.com/stock?t=UPB&ty=dv", "source_name": "Finviz", "published_at": "2026-07-06T04:39:31", "published_display": "06 Jul 2026 04:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Upstream Bio, Inc. \u2013 NASDAQ:UPB", "summary": "The article focuses on the \"Price to sales forward\" metric for Upstream Bio, Inc. (NASDAQ: UPB). It provides a snapshot of the company's financial data on TradingView, indicating that the market was closed at the time of viewing. The content is primarily a data point with no furt", "url": "https://www.tradingview.com/symbols/NASDAQ-UPB/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T09:40:51", "published_display": "04 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in UpStream Bio Inc. (UPB)", "summary": "This article examines the historical performance of a $1,000 investment in UpStream Bio Inc. (UPB), a clinical-stage biotechnology company focused on inflammatory diseases. It provides detailed information on UPB's core drug candidate, verekitug, its mechanism of action, and its ", "url": "https://www.stocktitan.net/tools/stock-return-calculator/UPB", "source_name": "Stock Titan", "published_at": "2026-07-04T05:11:19", "published_display": "04 Jul 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Watching Upstream Bio's (NASDAQ:UPB) Cash Burn Situation", "summary": "This article examines Upstream Bio's cash burn rate and its implications for the company's future operations. It analyzes the current cash reserves against the burn rate to estimate how long the company can continue funding its activities without additional capital. The article h", "url": "https://www.moomoo.com/news/post/72406755/here-s-why-we-re-watching-upstream-bio-s-nasdaq", "source_name": "Moomoo", "published_at": "2026-07-02T14:41:07", "published_display": "02 Jul 2026 14:41", "sentiment": "negative", "sentiment_pct": 29, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Upstream Bio, Inc. \u2013 NASDAQ:UPB", "summary": "The article focuses on the enterprise value to EBIT forward ratio for Upstream Bio, Inc., trading under the NASDAQ symbol UPB. It appears to be a financial data point presented within a trading platform context, with placeholders for actual financial figures.", "url": "https://www.tradingview.com/symbols/NASDAQ-UPB/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T17:40:34", "published_display": "29 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio, Inc. Actuals & Estimates (NASDAQ:UPB)", "summary": "This article provides an overview of Upstream Bio, Inc. (NASDAQ: UPB) stock, including its current price, market capitalization, historical performance, and analyst forecasts. It also details key financial actuals and estimates such as earnings per share and revenue, indicating t", "url": "https://www.tradingview.com/symbols/NASDAQ-UPB/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T19:09:53", "published_display": "26 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio, Inc. (UPB) reports Q1 loss, beats revenue estimates", "summary": "Upstream Bio, Inc. (UPB) reported a Q1 loss per share of $0.93, which was lower than the analyst estimate of a $1.09 loss per share. The company also announced Q1 revenue of $180,000, surpassing the analyst consensus estimate of $170,000.", "url": "https://www.msn.com/en-us/money/other/upstream-bio-inc-upb-reports-q1-loss-beats-revenue-estimates/ar-AA236hGq?ocid=BingNewsVerp", "source_name": "MSN", "published_at": "2026-06-26T11:09:53", "published_display": "26 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage?", "summary": "Upstream Bio, Inc. (NASDAQ:UPB) is highlighted as a promising small-cap stock following new analyst coverage from H.C. Wainwright, which initiated a Buy rating and a $36 price target. The analyst praised the company's lead candidate, verekitug, an antibody targeting the thymic st", "url": "https://www.insidermonkey.com/blog/is-upstream-bio-inc-upb-a-rising-biotech-opportunity-after-new-analyst-coverage-1788980/", "source_name": "Insider Monkey", "published_at": "2026-06-25T08:42:00", "published_display": "25 Jun 2026 08:42", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Upstream Bio, Inc. (UPB) the Best Low Priced Stocks to Get Rich in 2026?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPTTNHejRwTVFRTVgtRC1KRjgzQ0R3R0hSakVTVkxkR2VRczRaZXJlWHRpVUVVaFZpTFdFZ3ExaElEMzIxY3pieXcwdTd6emhSNmpzblgyNTJzSlVKTDdxRW9DQUg1V3V5ekk0Y0xRTzRuM0JLMWl1TFZadDcwMHFFYXMzZGo3ODNqNXNELXU3UVB3Zkd4?oc=5", "source_name": "Market source", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio Inc (UPB) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Upstream Bio Inc (UPB), covering its current price momentum, support and resistance levels, and various technical indicators and moving averages. According to the analysis, UPB's price momentum score is 6.46, and it's trading between ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-upb/technical", "source_name": "TradingKey", "published_at": "2026-06-18T01:40:17", "published_display": "18 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio Inc (UPB) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Upstream Bio Inc's (UPB) dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years and shows no data for past stock splits. The page includes current stock price information, marke", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-upb/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:39:18", "published_display": "17 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio Inc (UPB) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Upstream Bio Inc (UPB), noting its current valuation score is 8.14, ranking 168 out of 388 in the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -2.04 and states that relevant data for P/B", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-upb/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T04:10:07", "published_display": "17 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio Reports Positive Phase 2 Results for Verekitug in Chronic Rhinosinusitis with Nasal Polyps, Achieving Clinically Meaningful Improvements in Key Symptoms", "summary": "Upstream Bio announced positive Phase 2 results for its drug verekitug in treating chronic rhinosinusitis with nasal polyps (CRSwNP). The trial demonstrated significant improvements in nasal polyp scores and key secondary endpoints like nasal congestion and total symptom scores, ", "url": "https://www.quiverquant.com/news/Upstream+Bio+Reports+Positive+Phase+2+Results+for+Verekitug+in+Chronic+Rhinosinusitis+with+Nasal+Polyps%2C+Achieving+Clinically+Meaningful+Improvements+in+Key+Symptoms", "source_name": "Quiver Quantitative", "published_at": "2026-06-14T14:10:00", "published_display": "14 Jun 2026 14:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026", "summary": "Upstream Bio presented new responder analyses from its Phase 2 VIBRANT trial for verekitug, showing clinically meaningful improvements in chronic rhinosinusitis with nasal polyps (CRSwNP). The data indicated that approximately 80% of participants treated with verekitug every thre", "url": "https://www.globenewswire.com/news-release/2026/06/14/3311448/0/en/upstream-bio-presents-new-responder-analyses-demonstrating-clinically-meaningful-improvements-in-crswnp-in-significant-majority-of-participants-treated-with-verekitug-in-the-phase-.html", "source_name": "GlobeNewswire", "published_at": "2026-06-14T14:09:25", "published_display": "14 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quarterly nasal polyp treatment improved symptoms for most trial patients", "summary": "Upstream Bio presented new analyses from its Phase 2 VIBRANT trial for verekitug, showing clinically meaningful improvements in chronic rhinosinusitis with nasal polyps (CRSwNP) symptoms for a significant majority of patients with quarterly dosing. Approximately 80% achieved impr", "url": "https://www.stocktitan.net/news/UPB/upstream-bio-presents-new-responder-analyses-demonstrating-nf8nz0204l8c.html", "source_name": "Stock Titan", "published_at": "2026-06-14T14:09:25", "published_display": "14 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio Cut to Neutral From Overweight by JP Morgan", "summary": "JP Morgan has downgraded Upstream Bio's rating from Overweight to Neutral. This change in rating suggests a revised outlook on the company's stock performance by the investment bank.", "url": "https://www.moomoo.com/news/post/71464057/upstream-bio-cut-to-neutral-from-overweight-by-jp-morgan?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-13T12:10:12", "published_display": "13 Jun 2026 12:10", "sentiment": "negative", "sentiment_pct": 31, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan Downgrades Upstream Bio to Neutral From Overweight, Cuts Price Target to $8 From $35", "summary": "JPMorgan downgraded Upstream Bio (UPB) from Overweight to Neutral and significantly cut its price target from $35 to $8. This adjustment reflects a revised outlook from the investment bank regarding the biotechnology company. Upstream Bio is a clinical-stage biotechnology company", "url": "https://www.marketscreener.com/news/jpmorgan-downgrades-upstream-bio-to-neutral-from-overweight-cuts-price-target-to-8-from-35-ce7f5cd9d889f123", "source_name": "marketscreener.com", "published_at": "2026-06-12T11:09:34", "published_display": "12 Jun 2026 11:09", "sentiment": "negative", "sentiment_pct": 8, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "J.P. Morgan Downgrades UpStream Bio(UPB.US) to Hold Rating, Announces Target Price $8", "summary": "J.P. Morgan has downgraded UpStream Bio (UPB.US) from an Overweight to a Hold rating. The firm also announced a new target price of $8 for the company's stock. This change in rating reflects J.P. Morgan's updated outlook on UpStream Bio's financial performance and market potentia", "url": "https://www.moomoo.com/news/post/71452917/jp-morgan-downgrades-upstream-bio-upbus-to-hold-rating-announces", "source_name": "Moomoo", "published_at": "2026-06-12T10:09:34", "published_display": "12 Jun 2026 10:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio Shareholders Elect Directors, Ratify 2026 Auditor", "summary": "Upstream Bio, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders elected two Class II directors, H. Edward Fleming, Jr., M.D., and Liam Ratcliffe, M.B.Ch.B., Ph.D., M.B.A., to serve until the 2029 annual meeting. Investors also ratified PricewaterhouseCoopers L", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/2430605/upstream-bio-shareholders-elect-directors-ratify-2026-auditor/", "source_name": "The Globe and Mail", "published_at": "2026-06-10T16:10:12", "published_display": "10 Jun 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026", "summary": "Upstream Bio announced that additional efficacy data from its Phase 2 VIBRANT trial of verekitug in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) will be presented in an oral session at the European Academy of Allergy and Clinical Immunology (EAACI) 2026 Congres", "url": "https://www.globenewswire.com/news-release/2026/06/08/3307953/0/en/upstream-bio-to-showcase-additional-efficacy-data-from-the-phase-2-vibrant-trial-of-verekitug-in-crswnp-in-oral-session-at-eaaci-2026.html", "source_name": "GlobeNewswire", "published_at": "2026-06-08T22:08:53", "published_display": "08 Jun 2026 22:08", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nasal polyp drug Verekitug Phase 2 data to be aired at EAACI 2026", "summary": "Upstream Bio (NASDAQ: UPB) will present additional efficacy data from its Phase 2 VIBRANT trial of verekitug for chronic rhinosinusitis with nasal polyps (CRSwNP) at the EAACI 2026 Congress on June 14, 2026. The presentation will feature a responder analysis highlighting clinical", "url": "https://www.stocktitan.net/news/UPB/upstream-bio-to-showcase-additional-efficacy-data-from-the-phase-2-8nweqwjlmf8w.html", "source_name": "Stock Titan", "published_at": "2026-06-08T10:39:07", "published_display": "08 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio (UPB) price target decreased by 18.03% to 51.00", "summary": "Upstream Bio's price target has been decreased by 18.03% to $51.00. This adjustment indicates a notable change in the financial outlook for the company.", "url": "http://www.msn.com/en-us/money/topstocks/upstream-bio-upb-price-target-decreased-by-1803-to-5100/ar-AA1RPAnE?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-06-04T20:10:06", "published_display": "04 Jun 2026 20:10", "sentiment": "negative", "sentiment_pct": 13, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/upstream-bio-present-goldman-sachs-110000903.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T11:00:00+00:00", "published_display": "03 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HC Wainwright Initiates Upstream Bio at Buy With $36 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/hc-wainwright-initiates-upstream-bio-103025385.html", "source_name": "MT Newswires", "published_at": "2026-06-03T10:30:25+00:00", "published_display": "03 Jun 2026 10:30", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio: The Reset Is The Opportunity, Initiating At Buy (NASDAQ:UPB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPN0dxNnhiVkgwWHRxNnBwbDZ6RnFIM0xkUU5vVVIteWEzanJGRzBkMkVobEExLXJTY0hwSGFkRnJDcUpxU1NfVUJ0VnhkTmRreXFrVDU0UndxSG9WT3JXeUZQOXdUQTByYUcwdGFJbUdhazdyZGR1cmVtY2RkeXExNno5c0YzV0xVTFRDNlFFU3kwbHhianhmclc4N3ZxMWJGVm9wU3hkMA?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/upstream-bio-presents-data-phase-153000153.html", "source_name": "GlobeNewswire", "published_at": "2026-05-18T15:30:00+00:00", "published_display": "18 May 2026 15:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho Adjusts Price Target on Upstream Bio to $50 From $51, Maintains Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/mizuho-adjusts-price-target-upstream-102046798.html", "source_name": "MT Newswires", "published_at": "2026-05-14T10:20:46+00:00", "published_display": "14 May 2026 10:20", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Upstream Bio, Inc. (UPB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMia0FVX3lxTFBrcjB6YVhJOFFKWmhvbHZKZU1ZVTBXNUNONEpURkVlbG1odmFnbVd0bE1wZ2pXWEpsbmNBdGF4RDI2QkVIYkdaU2RVSV9hbnQtSk1mT21FcVdHZnhXeVd5TGM1Q2VZcWw0RUp3?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Companies Like Upstream Bio (NASDAQ:UPB) Are In A Position To Invest In Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNWTJkcnBwbmtxN205dzdCLTlDZGhGQUttRzhEVENnTVRhTEV4SXQ3ak1TN2xOQ3N3ODhhYV9OSTBabm9HbFh3RnlHODVvOExnVkFIekRvZldsOGM3SmJrYlhhUERaZF9IeENiTk1ZRVk4SW1yclVIWjcxLUZrc1pReldjanBMdw?oc=5", "source_name": "Market source", "published_at": "2026-02-15T08:00:00+00:00", "published_display": "15 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio: Hold Rating As Verekitug Faces Competition Among Latest Asthma Data (UPB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNSDgxSi1hdXFQQUlyRERkdVlpQi1KY3VZc0NjVjc2TFVCQVhheExGbzR4dGRMUXN1YlVPTXFwM1ZCSkNKR2g1SXZQb2Y3NEExM09WT01BWnUwRWtXSWpoV3VEelFIV1BSNmlCdFVkaHRqb0VCU3JwdGJKdU51cmZ3OVYwWUVFcTBXdWVNWHhfMUZScWY4Mkp0Qm94eUZKcUF6UGZsQXNiYjVvZFQxX1BsZXl6OUk4UGpGMjY5UWZB?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Upstream Bio (UPB) Valuation After Recent Share Price Volatility", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio\u2019s stock drops 47% on verekitug Phase II asthma data", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTE5UekJzNWN5UFhZTjJ0N1VwWEwtVEZmQjJuSHVzeEJ5TEF4WkszS1ZWUXpGZkN0YUVseU1UZF8ydUpSeF9vOTJIMHpqeHlYNHZfRmZVTVF4ZktqaWRDSHNjdk0xRmI0U0lzb3dmbkVpTUlTVWYwLW13SGF2T04xQQ?oc=5", "source_name": "Market source", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio Stock Pre-Market (+15%) : Positive Phase 2 Asthma Trial Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNbjcxbXNDTHJ4T05VMTVoSkttTFNqX1FFc2t3a2xQdTNTVUhYTjR5aUlWVzMxOW9nNzFBZGlfR1hnVkpUNmpIUmh4bm56bUlKRndTMkFON3drWVVXWDRQcENsZkxfQk1vX3ZSOWtpMXdvY3FGYUFLV2E2bmpYQVNYdXNIcHN3NU5XRHJyVDc0NkctRnhxbEtJUTg3VjdMSjVWWTYtZ1FJaUVwY3lxb1IwbFFBY296NUxFV0YtejJ3c0NHR0ZNdmc?oc=5", "source_name": "Trefis", "published_at": "2026-02-11T08:00:00+00:00", "published_display": "11 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio stock tumbles after mixed Phase 2 asthma trial results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPN2FKYWpvWGgwNFYzQXBSS0pCVzNlNzFWWHhWdTRmTld5WW1xU2JfbnFTRmlFTGhZYlJORktkOC16ZGZKY2twNjFvMXd3YW44YnU0cXF2OXVBQnBrclpzUDBsN0daSU9lM1BDc3lKNmkyc2tsU2pJOTN5dHp4c1Z6NkE5aVpMNnBpTUtaMW1MaENyMGU2VGVJNldHUHVKQm1YUWg1NlR4aEFOX1BOZTNMN0lfWlh1LW1jZG5KRFoyNkNyb08xdzRGNA?oc=5", "source_name": "Investing.com", "published_at": "2026-02-11T08:00:00+00:00", "published_display": "11 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Upstream Bio (UPB) Is Up 12.2% After JPM Debut And VALINAT Hopes", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-16T08:00:00+00:00", "published_display": "16 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Upstream Bio (UPB) Stock Price, News & Analysis $UPB", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWEFVX3lxTE5NcmUwckpPdER1SUtta3ZsS3IyVVUwU1Y4a1RDSlBRMHNoNDVrZnNxd2dQX0NFNE5JLVRBUkZBeks0OVZMQ2VydVBFT2kzekNBejh6d2FlMUM?oc=5", "source_name": "MarketBeat", "published_at": "2024-10-12T01:44:50+00:00", "published_display": "12 Oct 2024 01:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 91, "total_relevant": 48, "sentiment_summary": {"positive": 14, "negative": 7, "neutral": 27, "score": 52, "total": 48, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 13.35, "count": 23}, {"event": "earnings", "label": "Earnings", "weight": 6.05, "count": 13}, {"event": "analyst", "label": "Analyst action", "weight": 4.75, "count": 8}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 14, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 7.01, "latest_week": "2026-07-17", "one_week_move": -6.9, "four_week_move": 12.2, "twelve_week_move": -24.6, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.041942, "market_dynamics_buy_signal": false, "relative_strength": -62.506614, "fair_value_gap": -53.7, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 45.4449, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-6.9% over one week, +12.2% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 60, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 10}, {"label": "TradingView", "count": 6}, {"label": "GlobeNewswire", "count": 4}, {"label": "simplywall.st", "count": 4}, {"label": "Stock Titan", "count": 3}, {"label": "Moomoo", "count": 3}, {"label": "TradingKey", "count": 3}, {"label": "MSN", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 40}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 23}, {"label": "Earnings", "count": 13}, {"label": "Analyst action", "count": 8}, {"label": "Guidance", "count": 2}, {"label": "Balance sheet", "count": 1}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "40", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-6.9% over one week, +12.2% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "ETFs Investing in Upstream Bio, Inc. Stocks"}], "updated_at": "2026-07-18T16:03:20.790383+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}